$DHR 0.49 Noisy
- Date
- Jul 21, 2026
- Mentions
- 2
- Unique authors
- 1
- Sector
- biotech
- Stance
- mixed
- On card
- no
Sentiment history
No sentiment history available for $DHR yet.
Sentiment
Notable posts
-
neutral 62 eng
Today's Key Events (All EST) β 07/21/2026 08:15: US ADP Wkly Employment Change 08:55: US Redbook YoY Before Open π 06:45: Halliburton $HAL 06:30: General Motors $GM 06:30: 3M $MMM 07:30: Charles Schwab $SCHW 06:30: D.R. Horton $DHI 07:15: Ally Financial $ALLY 06:00: Danaher $DHR 06:45: MSCI $MSCI 07:20: Northrop Grumman $NOC Before Open: Novartis $NVS 06:30: Equifax $EFX 06:30: Hasbro $HAS 07:00: Marsh $MRSH 06:00: Synchrony Financial $SYF After Hours π 18:55: Alaska Air Group $ALK 16:05: Capital One $COF 16:00: Interactive Brokers $IBKR 16:05: Chubb $CB 16:30: EQT $EQT 16:15: Range Resources $RRC 16:05: Pegasystems $PEGA 16:25: Western Alliance $WAL
view on X β -
bullish 61 eng
DANAHER $DHR Q2β26 EARNINGS HIGHLIGHTS πΉ Revenue: $6.3B (Est. $6.27B) π‘; +5.5% YoY πΉ Adj. EPS: $1.94 (Est. $1.84) π’; +8.0% YoY πΉ FCF: $1.3B; +~15.5% YoY Raises FY26 Guide: πΉ Adj. EPS: $8.45-$8.60 (Est. $8.5) π‘ πΉ Core Revenue Growth: +3.0%-+4.0% Segment Revenue: πΉ Biotechnology: +4.0% YoY πΉ Life Sciences: +5.5% YoY πΉ Diagnostics: +7.0% YoY Business Highlights: πΉ Pending Acquisition: Leica Biosystems to acquire StatLab πΉ Masimo Acquisition: Completed earlier-than-anticipated, enabling increased FY26 Adj. EPS guidance Comments: πΈ βWe delivered a better than expected second quarter, with core growth improving versus the first quarter and disciplined execution driving high-single-digits adjusted EPS growth.β πΈ βLooking ahead, continued end-market recovery and traction from our recent growth initiatives support our expectation to exit 2026 at a mid-single-digit core revenue growth rate.β
view on X β
Only one day of history so far β the signal arc fills in as the daily job runs.